Evidence map›Paper›PMID 37961344›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Flipped C-Terminal Ends of APOA1 Promote ABCA1-dependent Cholesterol Efflux by Small HDLs.

Yi He, Chiara Pavanello, Patrick M Hutchins, Chongren Tang, Mohsen Pourmousa, Tomas Vaisar, Hyun D Song, Richard W Pastor, Alan T Remaley, Ira J Goldberg and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Yi HeDepartment of Medicine, University of Washington, Seattle, WA, 98109, USA.
Chiara PavanelloCentro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.
Patrick M HutchinsDepartment of Medicine, University of Washington, Seattle, WA, 98109, USA.
Chongren TangDepartment of Medicine, University of Washington, Seattle, WA, 98109, USA.
Mohsen PourmousaLaboratory of Computational Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Tomas VaisarDepartment of Medicine, University of Washington, Seattle, WA, 98109, USA.
Hyun D SongDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37240, USA.
Richard W PastorLaboratory of Computational Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Alan T RemaleyDepartment of Laboratory Medicine, National Institutes of Health, Bethesda, MD 20892.
Ira J GoldbergDepartment of Medicine, New York University, New York, NY, 10016, USA.
Tina CostacouDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
W Sean DavidsonDepartment of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45237, USA.
Karin E BornfeldtDepartment of Medicine, University of Washington, Seattle, WA, 98109, USA.
Laura CalabresiCentro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.
Jere P SegrestDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37240, USA.
Jay W HeineckeDepartment of Medicine, University of Washington, Seattle, WA, 98109, USA.
University of Washington · USNational Institutes of Health · USUniversity of Milan · ITVanderbilt University Medical Center · USNew York University · USUniversity of Cincinnati Medical Center · USUniversity of Pittsburgh · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY E. PESSIN · 2015 to 2026
$27.7M
Project 3 - HDL Structure/Function in LCAT Deficient HumansP01HL128203 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI W Sean Davidson · 2016 to 2026
$25.1M
Triglycerides, Diabetes and Cardiovascular DiseaseP01HL151328 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 2020 to 2026
$19.6M
CARDIOVASCULAR RESEARCH TRAINING PROGRAMT32HL007828 · NHLBI · UNIVERSITY OF WASHINGTON · PI Francis Kim, Farid Moussavi-Harami · 1997 to 2026
$10.2M
Identifying new strategies for prevention of cardiovascular complications of diabetesR35HL150754 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E · 2020 to 2025
$6.2M
Breakthrough Molecular Dynamics Research via an Anton2 SupercomputerR01GM116961 · NIGMS · CARNEGIE-MELLON UNIVERSITY · PI BLOOD, PHILIP D. · 2016 to 2023
$3.0M
HDL composition/function and cardiovascular risk in youths with diabetesR01HL144558 · NHLBI · UNIVERSITY OF WASHINGTON · PI VAISAR, TOMAS · 2019 to 2022
$2.8M
Structural basis for cardioprotective HDLR01HL149685 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E., HEINECKE, JAY W · 2020 to 2023
$2.8M
The structural basis for cholesterol esterification in human plasmaR01HL153118 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN · 2020 to 2023
$2.0M
The molecular basis for the role of apolipoprotein A-II in cholesterol and triglyceride metabolismR01HL155601 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN · 2021 to 2024
$1.5M
NHLBI NIH HHS P01 HL128203NHLBI NIH HHS P01 HL151328NHLBI NIH HHS R01 HL144558NHLBI NIH HHS R01 HL149685NHLBI NIH HHS R01 HL153118NHLBI NIH HHS R01 HL155601NHLBI NIH HHS R35 HL150754NHLBI NIH HHS T32 HL007828NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020541NIGMS NIH HHS R01 GM116961
6 · The paper itself

Abstract

Background: Cholesterol efflux capacity (CEC) predicts cardiovascular disease (CVD) independently of HDL cholesterol (HDL-C) levels. Isolated small HDL particles are potent promoters of macrophage CEC by the ABCA1 pathway, but the underlying mechanisms are unclear. Methods: We used model system studies of reconstituted HDL and plasma from control and lecithin-cholesterol acyltransferase (LCAT)-deficient subjects to investigate the relationships among the sizes of HDL particles, the structure of APOA1 in the different particles, and the CECs of plasma and isolated HDLs. Results: We quantified macrophage and ABCA1 CEC of four distinct sizes of reconstituted HDL (r-HDL). CEC increased as particle size decreased. MS/MS analysis of chemically crosslinked peptides and molecular dynamics simulations of APOA1 (HDL's major protein) indicated that the mobility of that protein's C-terminus was markedly higher and flipped off the surface in the smallest particles. To explore the physiological relevance of the model system studies, we isolated HDL from LCAT-deficient subjects, whose small HDLs-like r-HDLs-are discoidal and composed of APOA1, cholesterol, and phospholipid. Despite their very low plasma levels of HDL particles, these subjects had normal CEC. In both the LCAT-deficient subjects and control subjects, the CEC of isolated extra-small HDL (a mixture of extra-small and small HDL by calibrated ion mobility analysis) was 3-5-fold greater than that of the larger sizes of isolated HDL. Incubating LCAT-deficient plasma and control plasma with human LCAT converted extra-small and small HDL particles into larger particles, and it markedly inhibited CEC. Conclusions: We present a mechanism for the enhanced CEC of small HDLs. In smaller particles, the C-termini of the two antiparallel molecules of APOA1 are flipped off the lipid surface of HDL. This extended conformation allows them to engage with ABCA1. In contrast, the C-termini of larger HDLs are unable to interact productively with ABCA1 because they form a helical bundle that strongly adheres to the lipid on the particle. Enhanced CEC, as seen with the smaller particles, predicts decreased CVD risk. Thus, extra-small and small HDLs may be key mediators and indicators of HDL's cardioprotective effects.

Indexed as

ABCA1chemical crosslinkingcholesterol efflux capacitymolecular dynamics simulationpeptide analysis

Identifiers

PMID37961344
PMCPMC10635269
OpenAlexW4388331396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.